Home > Articles > Published articles > Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma |
Date: | 2022 |
Abstract: | Monitoring of the monoclonal protein (M-protein) by electrophoresis and/or immunofixation (IFE) has long been used to assess treatment response in multiple myeloma (MM). However, with the use of highly effective therapies, the M-protein becomes frequently undetectable, and more sensitive methods had to be explored. We applied IFE and mass spectrometry (EXENT&FLC-MS) in serum samples from newly diagnosed MM patients enrolled in the PETHEMA/GEM2012MENOS65 obtained at baseline (n 5 223), and after induction (n 5 183), autologous stem cell transplantation (n 5 173), and consolidation (n 5 173). At baseline, the isotypes identified with both methods fully matched in 82. 1% of samples; in the rest but 2 cases, EXENT&FLC-MS provided additional information to IFE with regards to the M-protein(s). Overall, the results of EXENT&FLC-MS and IFE were concordant in. 80% of cases, being most discordances due to EXENT&FLC-MS but IFE cases. After consolidation, IFE was not able to discriminate 2 cohorts with different median progression-free survival (PFS), but EXENT&FLC-MS did so; furthermore, among IFE patients, EXENT&FLC-MS identified 2 groups with significantly different median PFS (P 5. 0008). In conclusion, compared with IFE, EXENT&FLC-MS is more sensitive to detect the M-protein of patients with MM, both at baseline and during treatment, and provides a more accurate prediction of patients' outcome. This trial was registered at www. clinicaltrials. gov as #NCT01916252. |
Grants: | Instituto de Salud Carlos III CB16/12/00369 Instituto de Salud Carlos III CB16/12/00400 Instituto de Salud Carlos III CB16/12/00233 Instituto de Salud Carlos III CB16/12/00284 Instituto de Salud Carlos III PI15/01956 Instituto de Salud Carlos III PI18/01709 Instituto de Salud Carlos III PI18/01673 Instituto de Salud Carlos III PI19/01451 Ministerio de Economía y Competitividad PI15/02049 Ministerio de Economía y Competitividad PI15/02062 |
Note: | This study was supported by grants from the Centro de Inves-tigación Biomédica en Red-Área de Oncología-del Instituto de Salud Carlos III CIBERONC, CB16/12/00369, CB16/12/00400, CB16/12/00233, and CB16/12/00284, Instituto de Salud Carlos III/Subdirección General de Investigación Sanitaria FIS no. PI15/ 01956, PI15/02049, PI15/02062, PI18/01709, PI18/01673, and PI19/01451, the Cancer Research UK, FCAECC, and AIRC under the Accelerator Award Program (EDITOR). |
Rights: | Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades. |
Language: | Anglès |
Document: | Article ; recerca ; Versió publicada |
Published in: | Blood advances, Vol. 6 Núm. 11 (14 2022) , p. 3234-3239, ISSN 2473-9537 |
6 p, 919.4 KB |